Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Read more at MarketWatch
Topics
-
AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
Business - MarketWatch - November 12 -
AbbVie shares tumble after schizophrenia drug disappoints
Business - Financial Times - November 11 -
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
Business - CNBC - October 31 -
Bristol Myers’s stock pops as earnings top estimates and company raises guidance
Business - MarketWatch - October 31 -
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial
Business - MarketWatch - November 4 -
Reddit stock price soars after social media player reports rare profit
Top stories - CBS News - October 30 -
Stocks soar after decisive Trump victory
Top stories - NBC News - November 6 -
Microsoft's stock has worst day in two years after disappointing forecast
Business - CNBC - October 31
More from MarketWatch
-
Existing-home sales rise in October but remain at a low level
Business - MarketWatch - 7 minutes ago -
The actor Danny McBride’s best financial advice? Never buy a boat.
Business - MarketWatch - 8 minutes ago -
BJ’s stock rises on first membership-fee increase in 7 years
Business - MarketWatch - 19 minutes ago -
Beyond Inc. was set to rescue the Container Store. Now that’s off the table.
Business - MarketWatch - 20 minutes ago -
The last time inflation was projected to get worse, this investment was popular. Why it’s ‘unloved’ now.
Business - MarketWatch - 23 minutes ago